Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis
NCT07235384Phase 1Recruiting
- Sponsor
- Zai Lab
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of ZL-1503 in atopic dermatitis (AD) (2 arms), sponsored by Zai Lab. Primary endpoints: Adverse Events at 48 weeks, Serious Adverse Events at 48 weeks and 3 more. Started Dec 2025; status: recruiting.
02
Drugs
ZL-1503
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07235384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07235384.